Navigation Links
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
Date:9/18/2007

BOZEMAN, Mont., Sept. 18 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., today announced a strategic partnership with Biogen Idec (Nasdaq: BIIB) to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoimmune indications. CD103 is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

Under terms of the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.

"We are very pleased to be entering into this collaboration with Biogen Idec for the development of our lead anti-inflammatory therapy," said Donald P. Beeman, CEO and chairman of the board for LigoCyte. "This strategic alliance confirms the value of LigoCyte's immunology expertise."

About LigoCyte

LigoCyte Pharmaceuticals, Inc., is a privately held biopharmaceutical company developing vaccines and therapeutic monoclonal antibodies focused on important respiratory and gastrointestinal markets. The company is currently investigating its norovirus vaccine in human clinical studies. For more information on LigoCyte, please visit http://www.ligocyte.com.


'/>"/>
SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)...  In response to the opioid epidemic in ... working with Pfizer to make up to 1 million ... community health centers, free and charitable clinics, public health ... "Pfizer has a long-standing commitment to improving health outcomes ... through educational activities," said Caroline Roan , vice ...
(Date:5/23/2017)... Calif. , May 23, 2017  Leaf ... most innovative medical devices for pressure ulcer prevention, ... the American Association of Critical Care Nurses, National ... May 22-25. The Leaf Patient Monitoring ... specifically for the hospital environment.  The system seamlessly ...
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
Breaking Medicine Technology:
(Date:6/24/2017)... Fla. (PRWEB) , ... June 24, 2017 , ... ... is now offering genetic testing for medications in select Florida and Texas doctors' ... pharmacogenomics. , This new application of genetic testing recognizes the role genes ...
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... and will ultimately do significant harm to people with all chronic conditions, including ... "While it leaves in place the Affordable Care Act (ACA) requirement that insurers ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
Breaking Medicine News(10 mins):